New Products: NanoString Technologies' nCounter PanCancer Pathways Panel | GenomeWeb

NanoString Technologies this week launched its nCounter PanCancer Pathways Panel, a highly-multiplexed, digital gene expression assay that enables translational researchers to investigate cancer biology across all major cancer pathways.

From a single tube, the PanCancer Pathways Panel simultaneously analyzes 770 genes associated with all of the key cancer pathways: PI3K, STAT, MAPK, TGFβ, Notch, Hedgehog, Wnt, apoptosis, cell cycle, RAS, chromatin modification, transcriptional regulation, and DNA damage control.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.